PBTC29: Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma/ Brain Tumor


Brain Tumor : Gliomas


Low grade gliomas are among the most common primary CNS (central nervous system) neoplasms (an abnormal new mass of tissue that serves no purpose) of childhood.

Low-grade gliomas are also classified according to the location of the brain from which they originate. The commonly used therapies are surgery, chemotherapy and radiation. This study will determine the maximum tolerated dose of drug called AZD6244 (selumetinib) in children 12 years or over with gliomas which have returned following radiation and /or chemotherapy.The duration of the study will be four and half years.



Inclusion Criteria

For current eligibility status of this clinical study, the referring physician and/ or patient’s family may contact St. Jude’s Brain Tumor Coordinator at (901) 595-2544 or (901) 595-4599.


Ibrahim Qaddoumi, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN  38105 USA
Phone: 901-595-2365


Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: 901-595-2544
Fax: 901-595-5353

Contact us by email anytime, 24 hours a day, 7 days a week.


The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.